Sanofi: FDA Accepts to Review New Drug Application for Lixisenatide(GLP-1)
"The clinical program's results also showed that lixisenatide had a favorable safety and tolerability profile in most patients, with mild and transient nausea and vomiting."
http://www.foxbusiness.com/news/2013/02/19/sanofi-fda-accepts-to-review-new-drug-application-for-lixisenatide/